These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

575 related items for PubMed ID: 17040922

  • 21. Treatment of staphylococcal infections with cyclic lipopeptides.
    Eisenstein BI.
    Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():10-6. PubMed ID: 18226085
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN, Rybak MJ.
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [Abstract] [Full Text] [Related]

  • 23. The importance of the development of antibiotic resistance in Staphylococcus aureus.
    Schito GC.
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():3-8. PubMed ID: 16445718
    [Abstract] [Full Text] [Related]

  • 24. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT, Hsiao CH, Liao CH, Lee CW, Hsueh PR.
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [Abstract] [Full Text] [Related]

  • 25. Empirical therapy for serious Gram-positive infections: making the right choice.
    Segreti J.
    Clin Microbiol Infect; 2009 Dec; 15 Suppl 6():5-10. PubMed ID: 19917021
    [Abstract] [Full Text] [Related]

  • 26. Daptomycin: a review 4 years after first approval.
    Sauermann R, Rothenburger M, Graninger W, Joukhadar C.
    Pharmacology; 2008 Dec; 81(2):79-91. PubMed ID: 17940348
    [Abstract] [Full Text] [Related]

  • 27. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus.
    Kaka AS, Rueda AM, Shelburne SA, Hulten K, Hamill RJ, Musher DM.
    J Antimicrob Chemother; 2006 Sep; 58(3):680-3. PubMed ID: 16840428
    [Abstract] [Full Text] [Related]

  • 28. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
    Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP.
    J Antimicrob Chemother; 2003 Sep; 52(3):405-11. PubMed ID: 12917254
    [Abstract] [Full Text] [Related]

  • 29. Treatment of infections caused by resistant Staphylococcus aureus.
    Anstead GM, Quinones-Nazario G, Lewis JS.
    Methods Mol Biol; 2007 Sep; 391():227-58. PubMed ID: 18025681
    [Abstract] [Full Text] [Related]

  • 30. New agents for Staphylococcus aureus endocarditis.
    Drees M, Boucher H.
    Curr Opin Infect Dis; 2006 Dec; 19(6):544-50. PubMed ID: 17075329
    [Abstract] [Full Text] [Related]

  • 31. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW, Murray CK, Holmes RL, Patterson JE, Jorgensen JH.
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [Abstract] [Full Text] [Related]

  • 32. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS, Watters AA, Fritsche TR, Jones RN.
    BMC Infect Dis; 2007 Apr 18; 7():29. PubMed ID: 17442104
    [Abstract] [Full Text] [Related]

  • 33. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
    Garnacho-Montero J, Amaya-Villar R, Gómez-Grande ML, Jerez V, Lorente-Ramos L, Loza A, Martínez A, Pozo JC, Sierra R, Pomares J, de la Torre MV, Ortiz C.
    Rev Esp Quimioter; 2011 Mar 18; 24(1):13-24. PubMed ID: 21412665
    [Abstract] [Full Text] [Related]

  • 34. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
    Appelbaum PC.
    Int J Antimicrob Agents; 2007 Nov 18; 30(5):398-408. PubMed ID: 17888634
    [Abstract] [Full Text] [Related]

  • 35. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD.
    Int J Antimicrob Agents; 2007 Aug 18; 30(2):143-9. PubMed ID: 17531446
    [Abstract] [Full Text] [Related]

  • 36. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
    Jørgen B, Merckoll P, Melby KK.
    Scand J Infect Dis; 2007 Aug 18; 39(11-12):1059-62. PubMed ID: 17852934
    [Abstract] [Full Text] [Related]

  • 37. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis.
    Rouse MS, Piper KE, Jacobson M, Jacofsky DJ, Steckelberg JM, Patel R.
    J Antimicrob Chemother; 2006 Feb 18; 57(2):301-5. PubMed ID: 16361330
    [Abstract] [Full Text] [Related]

  • 38. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.
    Mangili A, Bica I, Snydman DR, Hamer DH.
    Clin Infect Dis; 2005 Apr 01; 40(7):1058-60. PubMed ID: 15825002
    [Abstract] [Full Text] [Related]

  • 39. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections.
    Kern WV.
    Int J Clin Pract; 2006 Mar 01; 60(3):370-8. PubMed ID: 16494659
    [Abstract] [Full Text] [Related]

  • 40. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT, Liao CH, Teng LJ, Hsueh PR.
    Clin Microbiol Infect; 2008 Feb 01; 14(2):124-9. PubMed ID: 18076671
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.